A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover

Bone

Volumn 24, Issue 6, 1999, Pages 603-609

  Garnero, P ^a   Darte, C ^b   Delmas, P D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b BECKMAN COULTER INC   (United States)

Author keywords

Alendronate; Bisphosphonate; Bone alkaline phosphatase; Bone marker; Dual energy X ray absorptiometry (DXA); Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; REGRESSION ANALYSIS; X RAY ANALYSIS;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MODELS, BIOLOGICAL; OSTEOPOROSIS, POSTMENOPAUSAL; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0032929449     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00087-3     Document Type: Article

References (17)

1. Chesnut C.H., Bell N.H., Clark G.S., et al. Hormone replacement therapy in postmenopausal women Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density . Am J Med. 102:1997;29-37.
2. Christiansen C., Riis B.J., Rodbro P. Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteopor Int. 1:1990;35-40.
3. Delmas P.D., Garnero P. Utility of biochemical markers of bone turnover in osteoporosis. Marcus R., Feldman D., Keysel J. Osteoporosis. 1996;1075-1085 Academic, San Diego, CA.
4. Garnero P., Delmas P.D. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab. 77:1993;1046-1053.
5. Garnero P., Shih W.J., Gineyts E., et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1994;1693-1700.
6. Garnero P., Sornay-Rendu E., Chapuy M.C., Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 11:1996;337-349.
7. Gordan G.S., Picchi J., Roof B.S. Antifracture efficacy of long term estrogens for osteoporosis. Trans Assoc Am Phys. 86:1973;326-332.
8. Hannon R., Blumsohn A., Naylor K., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy Impact of biological variability . J Bone Miner Res. 13:1998;1124-1133.
9. Hassager C., Jensen S.B., Gotfredsen A., Christiansen C. The impact of measurement errors on the diagnostic value of bone mass measurements Theoretical considerations . Osteopor Int. 1:1991;250-256.
10. Hosking D., Chilvers C.E.D., Christiansen C., et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 338:1998;485-492.
11. Hutchinson T.A., Polansky S.M., Feinstein A.R. Postmenopausal estrogens protect against fractures of hip and distal radius. Lancet. ii:1979;706-710.
12. Johansen J., Riis B.J., Delmas P.D., Christiansen C. Plasma BGP An indicator of spontaneous bone loss and the effect of estrogen treatment in postmenopausal women . Eur J Clin Invest. 18:1988;191-195.
13. Liberman U.A., Weiss S.R., Bröll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 33:1995;1437-1443.
14. Mizrahi I., Armour K., Emkey R., Marcus R., Santora A., Kress B. Clinical utility of bone specific alkaline phosphatase (BAP) (Tandem-R ostase) in monitoring individual postmenopausal osteoporotic women undergoing alendronate treatment. Arthr Rheum. 39:(Suppl. 9):1996;S86.
15. Riis B.J., Overgaard K., Christiansen C. Biochemical markers of bone turnover to monitor the bone mass response to postmenopausal hormone replacement therapy. Osteopor Int. 5:1995;276-280.
16. Rosen C.J., Chesnut C.H., Mallinak N.J.S. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement therapy or calcium supplementation. J Clin Endocrinol Metab. 82:1997;1904-1910.
17. Stepan J.J., Pospichal J., Presl J., et al. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone. 8:1987;279-284.